Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that it has received approval from China’s National Medical Products Administration (NMPA) to conduct a clinical study for its Category 1 antibody drug conjugate (ADC), SHR-7631, in patients with advanced solid tumors.
While the specific target of SHR-7631 remains undisclosed, Hengrui’s stock exchange notice highlights that the molecule is designed to specifically bind to target antigens on the surface of tumor cells, leading to internalization and the destruction of cancer cells. Currently, there is no similar product commercially available on the global market, making SHR-7631 a potentially groundbreaking therapy in the field of oncology.- Flcube.com
